Skip to content

RNA-seq maps genetic, nongenetic drivers of AML
For CML, the science is here now access must follow
Early intervention with daratumumab for smoldering myeloma may delay disease progression
EMA approves OT-C001 trial in DLBCL
Triplet ‘effective’ in relapsed or refractory AML

Join SOHO

Follow Us :

Home
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Roundtable Discussions
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Cellular Therapy

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Leukemia

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Lymphoma

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Multiple Myeloma

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Myelodysplastic Syndromes

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

April 29, 2025

Home
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Roundtable Discussions
Subscribe

SOHO Insider Hem/Onc Library Multiple Myeloma

Multiple Myeloma News

Multiple Myeloma

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

by SOHO Insider Editors
March 4, 2025
0 Comments

Multiple Myeloma

FDA grants Orphan Drug Designation for small-molecule MM therapy

by SOHO Insider Editors
February 27, 2025
0 Comments

Multiple Myeloma

Real-world study observes ‘superior’ outcomes with cilta-cel versus ide-cel for myeloma

by SOHO Insider Editors
February 26, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

Green light

Multiple Myeloma

FDA accepts BLA review for Blenrep combo in relapsed or refractory MM

by SOHO Insider Editors
February 10, 2025
0 Comments

patient data

Multiple Myeloma

Real-world study finds this triplet therapy is an option for daratumumab-refractory myeloma

by SOHO Insider Editors
February 10, 2025
0 Comments

Chronic Lymphocytic Leukemia Indolent B-Cell Lymphomas Lymphoma Multiple Myeloma

Is a stronger flu vaccine better for blood cancer patients?

by Leah Sherwood
February 3, 2025
0 Comments

Multiple Myeloma News

CARTITUDE-4 findings show improved health-related quality of life with cilta-cel for multiple myeloma

by SOHO Insider Editors
January 27, 2025
0 Comments

older adult patient

Cellular Therapy Multiple Myeloma News

Do older patients with myeloma respond as well to ide-cel as younger patients?

by Leah Sherwood
January 14, 2025
0 Comments

2024-2025 Happy New Year

Multiple Myeloma News Society Updates

Message from Editor-in-Chief Dr. Lonial: Advancing care amid uncertainty

by Leah Sherwood
January 13, 2025
0 Comments

1
2
3

POPULAR NEWS

MyeloMatch, NCI

Acute Myeloid Leukemia , Leukemia , Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

January 3, 2025

Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Neoplasms , News , Society Updates

Abstract submissions now open for SOHO 2025

February 14, 2025

Imatinib

66th American Society of Hematology Annual Meeting & Exposition , Leukemia

Asciminib benefit-risk profile bests other TKIs in CML

December 10, 2024

Top Categories

Cellular Therapy

10

Leukemia

31

Lymphoma

32

Multiple Myeloma

25

Myelodysplastic Syndromes

11

Myeloproliferative Neoplasms

8

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Categories

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Cellular Therapy

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Leukemia

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Lymphoma

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Multiple Myeloma

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Myelodysplastic Syndromes

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

Myeloproliferative Neoplasms

Subscribe

Recent Posts

RNA-seq maps genetic, nongenetic drivers of AML

Jerry Radich, MD

For CML, the science is here now access must follow

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Early intervention with daratumumab for smoldering myeloma may delay disease progression

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.